Westchester Capital Management (New York)’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.99M Buy
500,006
+6
+0% +$60 0.23% 98
2025
Q4
$4.95M Buy
+500,000
New +$4.94M 0.21% 88

Other funds holding DMII

Westchester Capital Management (New York)'s DMII Position: Q1 2026 in Review

Westchester Capital Management (New York) increased its Drugs Made In America Acquisition II Corp (DMII) stake by 0% in Q1 2026, buying an estimated $60 and bringing the position to 500,006 shares worth $4.99M. The position accounts for 0.23% of the portfolio, ranked #98.

Westchester Capital Management (New York) first reported a position in DMII in Q4 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • Westchester Capital Management (New York) held 500,006 shares of Drugs Made In America Acquisition II Corp worth $4.99M as of Q1 2026.
  • Westchester Capital Management (New York) bought 6 Drugs Made In America Acquisition II Corp shares in Q1 2026, an estimated $60.
  • Drugs Made In America Acquisition II Corp made up 0.23% of Westchester Capital Management (New York)'s portfolio in Q1 2026, its #98 holding.
  • Westchester Capital Management (New York) first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Westchester Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.